TSHA Taysha Gene Therapies
- 2.4250
- +0.0050+0.21%
Taysha Gene Therapies News
11 Analysts Assess Taysha Gene Therapies: What You Need To Know
Throughout the last three months, 11 analysts have evaluated Taysha Gene Therapies (NASDAQ:TSHA), offering a diverse set of opinions from bullish to bearish.In the table below, you'll find a summary o
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies with a Overweight and maintains $7 price target.
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today's pre-market trading after
Needham: Reiterates Taysha Gene Therapies (TSHA.US) rating and adjusted from buy to buy rating, target price is $7.00.
Needham: Reiterates Taysha Gene Therapies (TSHA.US) rating and adjusted from buy to buy rating, target price is $7.00.
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Taysha Gene Therapies with a Buy and maintains $7 price target.
Impact and Outlook: Taysha Gene Therapies Stock Analysis
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
Taysha Draws Bullish View at Piper Sandler on Lead Asset
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals Among Healthcare Movers
Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
7 analysts have expressed a variety of opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, offering a diverse set of opinions from bullish to bearish.In the table below, you'll find
Taysha Gene Therapies Initiated at Overweight by Piper Sandler
Taysha Gene Therapies Initiated at Overweight by Piper Sandler
Taysha Gene Therapies (TSHA.US) was covered for the first time by Piper Sandler, with an increase in holdings rating, with a target price of $9.00.
Taysha Gene Therapies (TSHA.US) was covered for the first time by Piper Sandler, with an increase in holdings rating, with a target price of $9.00.
Piper Sandler Initiates Coverage On Taysha Gene Therapies With Overweight Rating, Announces Price Target of $9
Piper Sandler analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight rating and announces Price Target of $9.
Buy Rating on Taysha Gene Therapies With TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growth
Analysis
Price Target
No Data
